Health, pharma and science writer at Reuters. Any opinions are mine.

Amgen cholesterol drug could get EU green light this week

businessinsider.com — By Ben Hirschler LONDON (Reuters) - Amgen's new cholesterol drug Repatha could be recommended for approval in Europe as early as this week, putting it ahead in a race with a rival product from Sanofi.

Amgen cholesterol drug could get EU green light this week

reuters.com — Repatha, or evolocumab, belongs to a new class of cholesterol-lowering drugs known as PCSK9 inhibitors that clinical trials suggest may slash the risks of heart attacks compared to standard treatment alone. According to an agenda posted on the European Medicines Agency's (EMA) website on Tuesday, a committee of experts will consider whether to recommend the medicine at a four-day meeting concluding on May 21.

Amgen cholesterol drug could get EU green light this week

reuters.com — Repatha, or evolocumab, belongs to a new class of cholesterol-lowering drugs known as PCSK9 inhibitors that clinical trials suggest may slash the risks of heart attacks compared to standard treatment alone. According to an agenda posted on the European Medicines Agency's (EMA) website on Tuesday, a committee of experts will consider whether to recommend the medicine at a four-day meeting concluding on May 21.

Amgen cholesterol drug could get EU green light this week

reuters.com — Repatha, or evolocumab, belongs to a new class of cholesterol-lowering drugs known as PCSK9 inhibitors that clinical trials suggest may slash the risks of heart attacks compared to standard treatment alone. According to an agenda posted on the European Medicines Agency's (EMA) website on Tuesday, a committee of experts will consider whether to recommend the medicine at a four-day meeting concluding on May 21.

How to build the universe from Lego, over a pint of beer

reuters.com — Across town, in different bars, other experts are probing the mysteries of cancer and dementia, life on other planets, and how to win a Nobel prize. It's all part of the May 18-20 "Pint of Science" festival, a fast-growing event that gives scientists a platform in dozens of drinking establishments across nine countries to explain their research to the public.

How to build the universe from Lego, over a pint of beer

businessinsider.com — By Ben Hirschler LONDON (Reuters) - In a central London pub, a young bearded physicist is demonstrating how to build a model of the universe from plastic Lego bricks. Clue: you need a lot of them. Across town, in different bars, other experts are probing the mysteries of cancer and dementia, life on other planets, and how to win a Nobel prize.

How to build the universe from Lego, over a pint of beer

dailymail.co.uk — LONDON, May 19 (Reuters) - In a central London pub, a young bearded physicist is demonstrating how to build a model of the universe from plastic Lego bricks. Clue: you need a lot of them. Across town, in different bars, other experts are probing the mysteries of cancer and dementia, life on other planets, and how to win a Nobel prize.

AstraZeneca drug combination on track to fight lung cancer

reuters.com — Researchers said on Wednesday that the combination of the experimental drugs MEDI4736 and tremelimumab had "a manageable safety profile with evidence of clinical activity, including in PD-L1 negative disease". The update was provided in a scientific summary, or abstract, released ahead of the annual meeting of the American Society of Clinical Oncology (ASCO) later this month.

AstraZeneca drug combination on track to fight lung cancer

businessinsider.com — By Ben Hirschler (Reuters) - A closely watched immune system-boosting drug cocktail from Britain's AstraZeneca shows promise in advanced lung cancer, despite adverse side effects in a number of patients. Researchers said on Wednesday that the combination of the experimental drugs MEDI4736 and tremelimumab had "a manageable safety profile with evidence of clinical activity, including in PD-L1 negative disease".

AstraZeneca drug combination on track to fight lung cancer

reuters.com — Researchers said on Wednesday that the combination of the experimental drugs MEDI4736 and tremelimumab had "a manageable safety profile with evidence of clinical activity, including in PD-L1 negative disease". The update was provided in a scientific summary, or abstract, released ahead of the annual meeting of the American Society of Clinical Oncology (ASCO) later this month.
More Articles →
May 18, 2015

It's Monday morning, so must be time for another multi-billion #drug deal --> #Endo to buy #Par for $8B reut.rs/1Fnj4hd $ENDP $PRX



Are You a Journalist?

Make a Portfolio

Create a free Muck Rack account to customize your profile and upload a portfolio of your best work.

Email

For instructions on how to pitch Ben Hirschler, email reutersbenhir@muckrack.com.


Share This Profile